COPD affects 391 million people worldwide—that’s equivalent to the population of 47 New York Cities or 44 Londons, 10 Tokyos, or 28 Rio De Janeiros. Yet despite its massive impact, COPD continues to be underprioritised, underfunded, and undertreated across healthcare systems globally. 1

Speak up for COPD

This #WorldCOPDDay, we urge healthcare systems worldwide to adopt standardized quality measures for diagnosis and management. Learn how to #SpeakUpforCOPD 1

This #WorldCOPDDay, we are urging healthcare providers and policymakers to take decisive action by implementing standardized quality measures for COPD diagnosis and management. Consistent care is a core element in improving patient outcomes and ensuring that everyone, regardless of location, age, gender, or economic background, has access to the right care plan and support.

COPD should no longer be sidelined. With increased attention, funding, and systemic changes, we can reshape how this disease is managed and elevate it to the public health priority it deserves to be.

Join us in the movement to empower patients, advocate for change, and act to improve care. Lend your voice and #SpeakUpforCOPD by visiting speakupforcopd.com to learn how you can make a difference in advancing the future of COPD care.

COPD vs World Cities Compared:

Patient Testimonials

Use the player’s top-right icon to see all the videos on this testimonial playlist.

Do you want to learn more about COPD or its impact on your country?

More information about COPD

Scientifically validated, up-to-date content for patients and the general public, simplified and adapted so everyone can understand.

Learn More

The Global State of COPD

Report

Download the Report

Communication grant for GAAPP Member Organizations

GAAPP has launched its communication grant for World COPD Day 2024.

A 200€ grant is offered to help us promote these resources from 10 November to 10 December 2024. The assets are available in English, French, German, Italian, Spanish and Portuguese.

To apply for the grant and obtain the social media assets, please click on the button below:

Apply for the Communication Grant

Speak Up for COPD is supported by a coalition of partners* across the industry and the non-profit sector. All partners contribute time and expertise to the coalition activities.

*Coalition partners: Global Allergy & Airways Patient Platform (GAAPP), International Federation of Ageing (IFA), COPD Foundation, International Coalition of Respiratory Nurses (ICRN), International Pharmaceutical Federation (FIP), with funding from AstraZeneca, GSK, Roche, Sanofi and Regeneron.

With generous support from our sponsors:

GSK logo

References

  1. Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modeling analysis. Lancet Respir Med. (2022) Vol 10(5); 447-458 [REF-162199]
  2. Bhutani M, et al. Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective. Adv Ther. 2022 Jun;39(6):2302- 2322. [REF-202070]
  3. Make B, Dutro MP, Paulose-Ram R, et al. (2012). Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chronic Obstruct Pulmon Dis. 7:1-9 [REF-80823]
  4. Quaderi, S. A., & Hurst, J. R. (2018). The unmet global burden of COPD. Global Health, Epidemiology, and Genomics, 3, e4. [REF-101911]
  5. AstraZeneca, Act on COPD. 2022. Common, Preventable, Treatable: Has COPD been underprioritised? [REF-202062]
  6. Mannino D, et al. Int J COPD. 2022:17; 749-761. Treatment Patterns for Chronic Obstructive Pulmonary Disease (COPD) in the United States: Results from an Observational Cross-Sectional Physician and Patient Survey. [REF-150456]
  7. AstraZeneca Data on file. 2023. A point prevalence study of COPD therapy in 13361 patients using the myCOPD app: examining real-time capture of disease control measures. [REF-205911]